Summary
During all phases of cancer treatment suppotive care and symptom control are important issues. This starts already in the diagnostic phase and has to be continued till the end of life. Nevertheless, symptoms and problems are often underestimated or even not recognized. This is especially true in brain tumour patients who, in comparison with other cancer patients, have a large number of relatively severe problems and concerns. The major problems reported by patients with primary or secondary brain tumours are headache, epileptic seizures, neurological deficit leading to disability, cognitive dysfunction, fatigue, depression, emotional and psychosocial distress, thromboembolic disease and complications from the use of drugs (corticosteroids, anticonvulsants and chemotherapy). Palliative treatment may initially be directed against the primary tumour or against metastatic disease. Only when these anti-tumour treatments have failed, palliative treatment will be primarily aimed at relief of symptoms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lidstone V, Butters E, Seed PT, Sinnott C, Beynon T, Richards M. Symptoms and concerns amongst cancer outpatients: identifying the need for specialist palliative care. Palliat Med, 17: 588–595, 2003
Schankin CJ, Ferrari U, Reinisch VM, Birnbaum T, Goldbrunner R, Straube A. Characteristics of brain tumour-associated headache. Cephalalgia, 27: 904–911, 2007
Klein M, Engelberts NHJ, van der Ploeg HM, Kasteleijn-Nolst Trenité DGA, Aaronson NK, Taphoorn MJB, Baaijen H, Vandertop WP, Muller M, Postma TJ, Heimans JJ. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol, 54: 514–520, 2003
Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman SA, Cairncross JG. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumours. Report of the quality standards subcommittee of the American Academy of Neurology. Neurology, 54: 1886–1893, 2000
Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol, 72: 255–260, 2005
Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumour patients. J Neurooncol, 78: 99–102, 2006
Sperling MR, Ko J. Seizures and brain tumours. Semin Oncol, 33: 333–341, 2006
Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol, 2: 404–409, 2003
Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T, Palmer JL. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol, 24: 2073–2078, 2006
Bruera E, El Osta B, Valero V, Driver LC, Pei BL, Shen L, Poulter VA, Palmer JL. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol, 25: 3475–3481, 2007
DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology, 39: 789–796, 1989
Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN, Ossenkoppele GJ, van Imhoff GW, Dekker AW, Jolles J, Slotman BJ, Struikmans H, Taphoorn MJB. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet, 360: 1361–1368, 2002
Torres IJ, Mundt AJ, Sweeney PJ, Llanes-Macy S, Dunaway L, Castillo M, Macdonald RL. A longitudinal neuropsychological study of partial brain radiation in adults with brain tumours. Neurology, 60: 1113–1118, 2003
Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol, 25: 1260–1266, 2007
Mainio A, Hakko H, Niemelä A, Koivukangas J, Räsänen P. Depression and functional outcome in patients with brain tumours: a population-based 1-year follow-up study. J Neurosurg, 103: 841–847, 2005
Ngo L, Nei M, Glass J. Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma. Epilepsia, 47: 1237–1238, 2006
Hassler M, Micksche M, Stockhammer G, Pichler J, Payer F, Abuja B, Deinsberger R, Marosi C. Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study. Wien Klin Wochenschr, 118: 230–238, 2006
Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Meneï P, Loiseau H, Bernier V, Honnorat J, Barrié M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY. Association of French-speaking Neuro-oncologists. Radiotherapy for glioblastoma in the elderly. N Engl J Med, 356: 1527–1535, 2007
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Heimans, J. Symptom control and supportive care in primary and secondary brain tumours. memo 1 (Suppl 2), 31–33 (2008). https://doi.org/10.1007/s12254-008-0031-4
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s12254-008-0031-4